

Yasutaka Takinishi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7439989/publications.pdf>

Version: 2024-02-01

21
papers

312
citations

1040056

9
h-index

888059

17
g-index

24
all docs

24
docs citations

24
times ranked

593
citing authors

#	ARTICLE	IF	CITATIONS
1	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	1.1	44
2	Heterozygous germline <i>BLM</i> mutations increase susceptibility to asbestos and mesothelioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 33466-33473.	7.1	30
3	Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). <i>Gastric Cancer</i> , 2018, 21, 421-427.	5.3	28
4	A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of <i>BAP1</i> and Other Germline Mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 3485-3494.	1.6	104
5	FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. <i>Journal of Translational Medicine</i> , 2017, 15, 58.	4.4	19
6	Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 29-36.	2.3	11
7	Randomized phase II study of cetuximab vs. irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study): Compared with ICECREAM study. <i>Annals of Oncology</i> , 2017, 28, iii109-iii110.	1.2	0
8	Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. <i>Investigational New Drugs</i> , 2015, 33, 1068-1077.	2.6	28
9	Investigation of the tolerability of FOLFIRINOX in patients with unresectable advanced pancreatic cancer: Single-institution experience in Japan.. <i>Journal of Clinical Oncology</i> , 2015, 33, 487-487.	1.6	1
10	Efficacy of self-expanding metal stent placement for gastric outlet obstruction caused by an unresectable malignant tumor. <i>Progress of Digestive Endoscopy</i> , 2015, 87, 152-153.	0.0	0
11	The Meaning of a Combination Use of Bevacizumab in Reintroduction of Oxaliplatin for Metastatic Colorectal Cancer. <i>Annals of Oncology</i> , 2014, 25, v71.	1.2	2
12	A phase I/II study of cetuximab (cet) in combination with S-1 and oxaliplatin (SOX) in first-line treatment for metastatic colorectal cancer (mCRC) (JACCRO CC-06).. <i>Journal of Clinical Oncology</i> , 2014, 32, 571-571.	1.6	5
13	Reintroduction of oxaliplatin for patients with metastatic colorectal cancer refractory to standard chemotherapy regimens.. <i>Journal of Clinical Oncology</i> , 2014, 32, 630-630.	1.6	1
14	A phase II study of cetuximab (cet) and mFOLFOX6 in metastatic colorectal cancer (mCRC) (JACCRO Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	0
15	Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer. <i>British Journal of Cancer</i> , 2013, 109, 2079-2086.	6.4	21
16	A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer: The SOFT study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3519-3519.	1.6	2
17	Randomized phase II study of S-1/CDDP plus TSU-68 versus S-1/CDDP in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 72-72.	1.6	1
18	Effect of L-NAME on the Synthesis of Plasma Fibrinogen in Mice. <i>Journal of Pharmacological Sciences</i> , 2005, 98, 94-98.	2.5	1

#	ARTICLE	IF	CITATIONS
19	Effects of Troglitazone on Diabetic Nephropathy and Hypercoagulation in KK and KK-A yMice Fed a High Fructose Diet. The Showa University Journal of Medical Sciences, 2004, 16, 109-116.	0.1	0
20	The Churgâ€“Strauss Syndrome after Pranlukast Treatment in a Patient Not Receiving Corticosteroids. Annals of Internal Medicine, 2003, 139, 386.	3.9	9
21	Tauroursodeoxycholic Acid Prevents Glycochenodeoxycholic Acid-induced Apoptosis. The Showa University Journal of Medical Sciences, 2003, 15, 265-277.	0.1	1